Nureca promoter holding rises to 68.09% post buyback

1 min read     Updated on 09 Jul 2026, 11:44 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Nureca Limited's promoter group increased its stake to 68.09% after a buyback that concluded on December 24, 2025, with shares extinguished on January 07, 2026. The total equity share capital reduced from 100,001,750 to 95,419,200, while the number of shares held by promoters remained constant at 64,97,176.

powered bylight_fuzz_icon
45123251

*this image is generated using AI for illustrative purposes only.

Nureca Limited disclosed that its promoter group's shareholding increased to 68.09% following a recent buyback of equity shares. The buyback, which opened on December 18, 2025, and closed on December 24, 2025, led to the extinguishment of shares on January 07, 2026. Consequently, the promoters' equity share capital and voting rights increased, although the number of shares held by them remained unchanged at 64,97,176.

The disclosures were submitted to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 29(1) and 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirers included Saurabh Goyal, Aryan Goyal, Payal Goyal, Smita Goyal, and Nectar Biopharma Private Limited.

The equity share capital of the company before the acquisition was 100,001,750, which reduced to 95,419,200 after the extinguishment of shares. The total diluted share capital post-acquisition stood at 95,419,200. The public shareholding decreased by 4,58,255 shares, bringing the public holding down to 31.91%.

Shareholding Pattern

The following table details the shareholding of the promoter and promoter group before and after the buyback:

Name of Acquirer Before the Buyback After the Buyback Difference
No. of shares % No. of shares % %
Saurabh Goyal 32,17,214 32.17 32,17,214 33.72 1.55
Aryan Goyal 11,59,185 11.59 11,59,185 12.15 0.56
Payal Goyal 20,59,928 20.60 20,59,928 21.59 0.99
Smita Goyal 7 0.00 7 0.00 0.00
Nectar Biopharma Private Limited 60,842 0.61 60,842 0.64 0.03
Promoters Total 64,97,176 64.97 64,97,176 68.09 3.12
Public 35,02,999 35.03 30,44,744 31.91 -3.12
Total 1,00,00,175 100.00 95,41,920 100.00

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
+12.01%+20.10%+18.51%-3.16%-4.04%-82.96%

How will the reduced public float impact the liquidity and trading volume of Nureca Limited shares?

Does the increased promoter stake signal a potential delisting or a move to tighten corporate control?

What is the company's planned utilization of capital following the significant reduction in equity share capital?

Nureca FY26 PAT rises 146%, led by revenue surge

0 min read     Updated on 08 Jul 2026, 04:54 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Nureca Limited reported a 146.10% increase in profit after tax to ₹20.82 million for the financial year ended March 31, 2026. Revenue from operations grew by 34.02% to ₹1,469.93 million, while EBITDA increased by 68.94% to ₹82.78 million.

powered bylight_fuzz_icon
45055433

*this image is generated using AI for illustrative purposes only.

Nureca Limited reported a 146.10% increase in profit after tax to ₹20.82 million for the financial year ended March 31, 2026. Revenue from operations grew by 34.02% to ₹1,469.93 million, while EBITDA increased by 68.94% to ₹82.78 million.

The company’s gross merchandise value (GMV) rose 17.51% to ₹2,029.86 million. EBITDA margin improved to 5.63% from 4% in the previous year. Net profit margins also improved to 1.47% from 1.07%.

Financial Performance

Metric FY25-26 FY24-25
Revenue from operations (₹ million) 1,469.93 1,096.61
PAT (₹ million) 20.82 8.46
EBITDA (�n million) 82.78 49.00
EBITDA Margin (%) 5.63 4.00

Operational Highlights

The company’s growth was driven by a 34.02% increase in revenue from operations. The cost of goods sold, which constitutes 63.06% of revenue, increased by 36.26% to ₹926.76 million. Other expenses rose 9.40% to ₹370.69 million, primarily due to a fair value loss of ₹83.50 million on investments.

Net worth decreased by 6.96% to ₹1,807.60 million, largely due to a share buyback. The company extinguished 4,58,255 equity shares during the year, resulting in an outflow of ₹151.22 million.

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
+12.01%+20.10%+18.51%-3.16%-4.04%-82.96%

How will the recent share buyback impact Nureca's capital allocation strategy moving forward?

What measures is the company taking to mitigate the fair value losses on investments observed this year?

Can the improved EBITDA margins be sustained given the rising cost of goods sold?

More News on Nureca

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-4.04%